IR-Med to present at National Pressure Injury Advisory Panel 2023

The company’s PressureSafe device is being designed to reduce healthcare disparity in pressure injury detection and treatment Rosh Pina, Israel, March 14, 2023 (GLOBE NEWSWIRE) — “IR-MED” or the “Company”) (OTCQB:IRME), will be presenting its proprietary technology that is being designed to detect early-stage Pressure Injuries (PI) at the Annual Conference of the National Pressure […]

Biotech In 2023: Making Its Mark On The Future Of Healthcare

Technology continues to be the driving force behind new generations of innovation—and the healthcare field is not immune to its impact, especially when it comes to the accuracy and efficiency that artificial intelligence is bringing to biotechnology. Life-saving drugs developed at record speed, advancements in gene editing breakthroughs that inform more efficacious preventive care regimes, […]

3 Advancements in Biotech Investors Should Look Out for in 2023

Biotechnology is a vast field that influences various industries from agriculture, food engineering and clothing to the popular health-tech industry. It’s no wonder that during the past year most biotech stocks behaved relatively steadily in the market when compared to other industries, according to the S&P Biotech index (XBI) and Nasdaq Biotechnology index (NBI). Though we experienced a bear […]

IR-Med Announces $3.2 Million Private Placement

ROSH PINNA, Israel, April 14, 2022–(BUSINESS WIRE)–IR-Med (“IR-MED or the “Company”) (OTCQB:IRME), an innovative development stage medical device company that utilizes Infra-Red light spectroscopy (IR) combined with Artificial Intelligence (AI) technologies, announced that it has entered into a Subscription Agreements with certain investors for the sale of 3,636,364 shares at a per share price of […]

Following Its Recent Annual Updates: IR-Med Announces OTCQB Up-listing: “A Significant Achievement for the Company”

ROSH PINNA, Israel, January 25, 2022–(BUSINESS WIRE)–IR-Med (“IR-Med or the “Company“) (OTC:IRME) is pleased to announce that IR-Med has been approved by OTC Markets to up-list from Pink Sheet to the OTCQB tier after IR-Med satisfied the required uplist criteria. Effective as of February 1st, 2022, IR-Med will trade on the OTCQB exchange under its current symbol […]